Search

News Pain Relief and Functional Score Improvement in Patients with Low Rheumatoid Arthritis Activity: Baricitinib vs. Adalimumab

In patients with rheumatoid arthritis, pain and functional impairment may persist even with good disease activity control. An exploratory analysis of the RA-BEAM study compared the effects of baricitinib, adalimumab, and placebo added to methotrexate on residual pain and functional scores in patients with rheumatoid arthritis (RA) who achieved remission or low disease activity with this treatment.

Source: Biological Treatment 20. 2. 2020

News Efficacy of Combination Therapy for Chronic Lymphocytic Leukemia in Patients with Complex Karyotype

A complex karyotype (presence of ≥ 3 chromosomal abnormalities) is a negative prognostic marker in chronic lymphocytic leukemia (CLL). An analysis of the impact of complex karyotype on the efficacy of targeted CLL therapy combining the monoclonal antibody against CD20 antigen obinutuzumab with the BCL2 inhibitor venetoclax or the alkylating cytostatic chlorambucil was published in the journal Blood.

Source: Chronic Lymphocytic Leukemia 22. 4. 2020

News Risk of Developing Inhibitors in People with Milder Forms of Hemophilia

Moderate and mild hemophilia A differ from the severe form not only in clinical course and bleeding risk, but also in the risk of developing neutralizing antibodies (inhibitors).

Source: Hemophilia 1. 11. 2021

News How to Secure Diabetics with Atrial Fibrillation During PCI?

Optimal management of patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) continues to be the subject of studies. A sub-analysis of the RE-DUAL study focused on this issue in a high-risk group of patients with diabetes.

Source: Anticoagulant Treatment 29. 9. 2020

News Undiagnosed Hereditary Angioedema in Pregnancy –⁠ Case Study

Delayed diagnosis or misdiagnosis is not uncommon with hereditary angioedema (HAE), especially during pregnancy and the postpartum period. A case study by Canadian authors illustrates that HAE should be considered in the differential diagnosis for any patient with unexplained abdominal pain and recurrent swellings without the presence of urticaria.

Source: Hereditary Angioedema 8. 12. 2022

News Fixed Combination of Tiotropium/Olodaterol in SMI Inhaler and Its Benefits in COPD Treatment

The TRONARTO study, whose conclusions were published in the International Journal of Chronic Obstructive Pulmonary Disease, addressed the issue of inhalation therapy in patients with chronic obstructive pulmonary disease (COPD). The authors focused on the effect of the combination of tiotropium and olodaterol in an SMI (soft mist inhaler) type inhaler.

Source: COPD 20. 12. 2021

News Addition of ixazomib to lenalidomide and dexamethasone in multiple myeloma −⁠ Data from real-world Czech practice

A group of Czech and Slovak experts led by Associate Professor Jiří Minařík from the Hemato-Oncology Clinic of the Faculty of Medicine UP and University Hospital Olomouc published the final results of an observational study evaluating the addition of ixazomib to the combination with lenalidomide and dexamethasone in patients with relapsing/refractory multiple myeloma (RRMM). This involves experiences from real clinical practice, with data obtained from the Czech Registry of Monoclonal Gammopathies.

Source: Hematologic Malignancies 22. 12. 2022

News Good news for sleep in patients with axial spondyloarthritis –⁠ ixekizumab effectively reduces night-time back pain

The targeted treatment of axial spondyloarthritis currently relies on the anti-inflammatory effects of tumor necrosis factor (TNF) inhibitors, interleukin IL-17 inhibitors, and Janus kinase (JAK) inhibitors. Besides the objective efficacy of these targeted treatments, it is crucial to describe their influence on subjective symptoms for decision-making in clinical practice. The evaluation of the analgesic effect of ixekizumab (IXE) was provided by the randomized controlled trial COAST-V.

Source: Biological Treatment 14. 11. 2022

News Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population

Obesity is classified as a lifestyle disease with increasing prevalence and a rising contribution to morbidity and mortality in the general population. The epidemic of overweight and obesity also does not spare individuals with hemophilia. According to epidemiological data, the prevalence of obesity is also increasing in this population, causing a number of complications in many health aspects.

Source: Hemophilia with Movement 30. 5. 2022

News Third Generation Targeted Therapy for ROS1-Positive NSCLC

The potent third-generation tyrosine kinase inhibitor, lorlatinib, has shown activity in preclinical studies against nearly all known mutations in the ALK and ROS1 genes that lead to resistance to crizotinib treatment. Moreover, lorlatinib crosses the blood-brain barrier, offering hope for patients with CNS metastases. The results of a clinical evaluation of the efficacy and safety of lorlatinib in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) were published in The Lancet Oncology.

Source: Genetic Profile and Treatment of NSCLC 15. 4. 2020

News Is it safe to start dabigatran in the first days after ischemic stroke?

For patients after cardioembolic ischemic stroke (iCMP), starting anticoagulant therapy is crucial, but it is not strictly defined how many days after iCMP it is ideal to begin. The article provides a summary of a recent observational study that investigated the appropriate timing of starting dabigatran in patients with non-valvular atrial fibrillation (NVAF) after their first iCMP who were treated with intravenous thrombolysis or endovascular thrombectomy.

Source: Anticoagulant Treatment 27. 8. 2021

News Alemtuzumab –⁠ Does Age Matter? Or Not?

The authors of a study published this year focused on the safety and efficacy of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS). How did it perform over the observed period in patients of different age categories?

Source: Multiple Sclerosis 18. 10. 2021

News Subcutaneous pdC1-INH in Patients with Hereditary Angioedema in Real-World Practice

Italian authors published a series of cases of patients with hereditary angioedema caused by C1 inhibitor deficiency (C1-INH-HAE) with long-term prophylaxis using human plasma-derived C1 inhibitor concentrate (pdC1-INH) in subcutaneous form. They supplement the results of the placebo-controlled COMPACT study, in which s.c. pdC1-INH reduced the frequency of attacks, with insights from real-world practice in 5 patients treated at the angioedema therapy center in Milan, Italy.

Source: Hereditary Angioedema 27. 4. 2023

News Interactive Case Study: AATD –⁠ Alpha-1-Antitrypsin Deficiency

We present a case study of a man who was 41 years old at the time of his first contact with a pulmonary doctor. He came with symptoms of allergic seasonal rhinoconjunctivitis, proven sensitivity to spring trees, grasses, and dust mites, otherwise healthy, a parrot breeder. He is a former smoker with a smoking history of 20 pack-years. He was examined for exertional dyspnea, cough, recurrent respiratory infections, and wheezing. Try to follow the further diagnostic procedure and considerations with us, where you can choose between different options. At the same time, you will verify whether you proceeded correctly, along with the justification for the step taken.

Source: Deficiency of Alpha-1-Antitrypsin 19. 4. 2022

News Positive Effect of Diosmin on Venous Disease in Terms of Factors Responsible for Angiogenesis

A study published last year monitored the impact of diosmin on laboratory and clinical parameters related to the pathophysiology of chronic venous disease in patients.

Source: Venous Insufficiency 23. 4. 2020